Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.28 USD
Change Today -0.84 / -2.26%
Volume 956.9K
HRTX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

heron therapeutics inc (HRTX) Snapshot

Open
$37.64
Previous Close
$37.12
Day High
$39.12
Day Low
$36.12
52 Week High
09/3/15 - $39.12
52 Week Low
10/13/14 - $6.51
Market Cap
1.3B
Average Volume 10 Days
1.5M
EPS TTM
$-2.79
Shares Outstanding
35.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HERON THERAPEUTICS INC (HRTX)

Related News

No related news articles were found.

heron therapeutics inc (HRTX) Related Businessweek News

No Related Businessweek News Found

heron therapeutics inc (HRTX) Details

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company’s lead product candidate, SUSTOL (granisetron Injection, extended release), is being developed for the prevention of acute- and delayed chemotherapy-induced nausea and vomiting. The company resubmitted a new drug application for SUSTOL to the U.S. Food and Drug Administration. In addition, it is developing HTX-011, which is in Phase II clinical development for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

59 Employees
Last Reported Date: 03/13/15
Founded in 1983

heron therapeutics inc (HRTX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $540.8K
President and Director
Total Annual Compensation: $540.8K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $285.0K
Senior Vice President of Technical Operations
Total Annual Compensation: $395.0K
Compensation as of Fiscal Year 2014.

heron therapeutics inc (HRTX) Key Developments

Heron Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Heron Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations was $23,014,000 against $18,791,000 a year ago. Net loss was $23,107,000 or $0.74 per basic and diluted share against $19,011,000 or $0.78 per basic and diluted share a year ago. For the six months, the company reported loss from operations was $43,374,000 against $36,113,000 a year ago. Net loss was $43,677,000 or $1.45 per basic and diluted share against $36,549,000 or $1.52 per basic and diluted share a year ago. The company’s net cash used for operating activities for the three and six months ended June 30, 2015 was $15.8 million and $35.5 million, respectively, compared to net cash used for operating activities of $12.5 million and $28.2 million, respectively, for the same periods in 2014. The increases in net cash used for operating activities and net loss in 2015 as compared to 2014 were primarily due to clinical and manufacturing costs related to Phase 1 and Phase 2 clinical studies for HTX-011, as well as costs associated with the development of HTX-019.

Heron Therapeutics, Inc. to Report Q2, 2015 Results on Aug 07, 2015

Heron Therapeutics, Inc. announced that they will report Q2, 2015 results Pre-Market on Aug 07, 2015

Heron Therapeutics, Inc. Initiates Second Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain

Heron Therapeutics, Inc. announced that it has initiated a second Phase 2 clinical trial of HTX-011. HTX-011, which utilizes Heron’s proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The placebo-controlled, dose-finding, Phase 2 clinical trial in approximately 60 patients undergoing inguinal hernia repair will evaluate the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine combined with meloxicam, compared to placebo. HTX-011 is also currently being evaluated in a placebo-controlled, dose-finding, Phase 2 clinical trial in patients undergoing bunionectomy. In a previously completed, placebo-controlled, Phase 1 clinical trial, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam, with therapeutically relevant plasma bupivacaine levels sustained for 2-3 days.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HRTX:US $36.28 USD -0.84

HRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foamix Pharmaceuticals Ltd $9.77 USD -0.34
Johnson & Johnson $92.64 USD -0.71
Sanofi €88.09 EUR -1.42
TESARO Inc $53.05 USD -0.35
View Industry Companies
 

Industry Analysis

HRTX

Industry Average

Valuation HRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HERON THERAPEUTICS INC, please visit www.herontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.